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Mild traumatic brain injury (mTBI) results in variable clinical outcomes, which may be influenced 
by genetic variation. A single-nucleotide polymorphism in catechol-o-methyltransferase (COMT), 
an enzyme which degrades catecholamine neurotransmitters, may influence cognitive deficits 
following moderate and/or severe head trauma. However, this has been disputed, and its role in 
mTBI has not been studied. Here, we utilize the Transforming Research and Clinical Knowledge 
in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) study to investigate whether the COMT 
Val158Met polymorphism influences outcome on a cognitive battery 6 months following mTBI—
Wechsler Adult Intelligence Test Processing Speed Index Composite Score (WAIS-PSI), Trail 
Making Test (TMT) Trail B minus Trail A time, and California Verbal Learning Test, Second 
Edition Trial 1–5 Standard Score (CVLT-II). All patients had an emergency department Glasgow 
Coma Scale (GCS) of 13–15, no acute intracranial pathology on head CT, and no polytrauma as 
defined by an Abbreviated Injury Scale (AIS) score of ≥3 in any extracranial region. Results in 
100 subjects aged 40.9 (SD 15.2) years (COMT Met158/Met158 29 %, Met158/Val158 47 %, 
Val158/Val158 24 %) show that the COMT Met158 allele (mean 101.6±SE 2.1) associates with 
higher nonverbal processing speed on the WAIS-PSI when compared to Val158/Val158 
homozygotes (93.8±SE 3.0) after controlling for demographics and injury severity (mean increase 
7.9 points, 95 % CI [1.4 to 14.3], p=0.017). The COMT Val158Met polymorphism did not 
associate with mental flexibility on the TMT or with verbal learning on the CVLT-II. Hence, 
COMT Val158Met may preferentially modulate nonverbal cognition following uncomplicated 
mTBI.
Keywords
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Introduction
Traumatic brain injury (TBI)—defined as an alteration in brain function, or other evidence 
of brain pathology, caused by an external force—is a comparatively common insult with 
variable outcomes [1, 2]. In the USA alone, at least 2.5 million people suffer TBIs annually 
[3], and it has been estimated that up to 5.3 million people are currently living with TBI-
related disability [4]. TBI is frequently subdivided on the basis of injury severity into severe, 
moderate, and mild injury categories as defined by a Glasgow Coma Scale (GCS) score of 8 
or less, 9-to-12, or 13-to-15, respectively [5, 6]. Although more severe injuries may 
disproportionately contribute to disability, the vast majority—70 to 90 %—of all TBI is 
characterized as “mild TBI” (mTBI) [7]. Within mTBI, considerable variability in outcome 
exists across individuals. Most make a complete recovery following mTBI [8, 9]; however, 
up to 20 % of patients experience persistent symptoms and/or cognitive or neuropsychiatric 
deficits [10]. Individuals with nearly identical injuries often manifest different symptoms, 
follow different clinical trajectories, and/or have varied functional outcomes [11]. Efforts are 
therefore needed to better identify those at greatest risk for posttraumatic sequela to better 
prognosticate and facilitate development of tailored therapy [1].
Studies have begun to investigate relationships between genetic variants within a number of 
candidate genes and outcome following TBI in an effort to elucidate such variability. One 
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form of this variance—called single nucleotide polymorphisms (SNPs)—is comprised of 
single nucleotide substitutions arising within a gene’s coding sequence and/or regulatory 
elements which may influence either protein structure/function or abundance, respectively. 
Numerous polymorphisms have been identified [12–14], but those arising within genes 
encoding important proteins underlying neurotransmission are thought to play an influential 
role in the preservation and/or impairment in cognition following TBI [15]. Catechol-O-
methyltransferase (COMT; encoded by the gene COMT on chromosome 22q11.2) represents 
one such molecule [16–18] and is an enzyme which inactivates catecholamine 
neurotransmitters, e.g., dopamine (DA), epinephrine, and norepinephrine, through 3-O-
methylation of the benzene ring [19]. In brain regions important to cognition, e.g., the 
prefrontal cortex (PFC), low expression of DA reuptake transporters makes COMT 
inactivation the predominant regulator of dopaminergic synaptic transmission [19–21].
A relatively common SNP arising within the coding sequence at codon 158—known as 
COMT Val158Met (rs4680)—results in substitution of a methionine for valine at this 
position [19]. This substitution lessens the activity of COMT resulting in higher levels of 
dopamine in the PFC [22], and it has been shown that Val158/Val158 individuals are up to 
four times more efficient at catabolizing catecholamines than Met158/Met158 homozygotes 
[23]. In turn, higher bioavailability of catecholamines in the PFC in Met158/Met158 subjects 
has been shown to confer a cognitive advantage over Val158-carriers [24], and the Met158 
allele is generally associated with an advantage in measures of memory, executive function, 
and tasks requiring attention [18, 25].
Cognitive symptoms, including memory loss, inattention, and impulsivity, are relatively 
common in TBI and are among the most debilitating consequences of TBI and may 
influence functional outcome [26]. A number of prior studies have suggested that disruption 
and/or dysregulation of dopaminergic transmission in the PFC may contribute to the 
pathogenesis of posttraumatic cognitive impairment [27]. Conversely, it has been suggested 
in other studies that the dopaminergic system may be pharmacologically targeted to 
ameliorate persistent cognitive deficits following TBI [28]. Despite its importance in 
modulating PFC neurotransmission, studies examining the relationship between the COMT 
Val158Met polymorphism and cognitive deficits following TBI have largely been equivocal 
[16–18]. To date, these studies have been limited to more severe injury, and whether the 
COMT Val158Met polymorphism influences posttraumatic cognitive deficits following 
mTBI has yet to be studied.
Here, we utilize the Transforming Research and Clinical Knowledge in Traumatic Brain 
Injury Pilot (TRACK-TBI Pilot) dataset, a database of demographic history, biomarkers, 
neuroimaging, and neuropsychiatric and neurocognitive outcomes obtained at three clinical 
sites [29], to evaluate whether the COMT Val158Met polymorphism influences cognitive 
performance 6 months following mTBI on a battery of three standardized tests—Wechsler 
Adult Intelligence Scale Fourth Edition Processing Speed Index subscale, Trail Making Test, 
and the California Verbal Learning Test Second Edition. We hypothesized that the COMT 
Val158Met polymorphism is associated with improved cognitive performance following 
mTBI. Our data demonstrates that the COMT Val158Met polymorphism associates with 
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cognitive performance in select domains, e.g., nonverbal processing speed, but not others, 
e.g., mental flexibility or verbal learning.
Materials and methods
Study design
The TRACK-TBI Pilot Study is a multicenter prospective observational study conducted at 
three Level 1 trauma centers in USA—San Francisco General Hospital, University of 
Pittsburgh Medical Center, and University Medical Center Brackenridge (UMCB) in Austin, 
Texas [29]—using the National Institutes of Health (NIH) and National Institute of 
Neurological Disorders and Stroke (NINDS) common data elements (CDEs) [30–33]. 
Inclusion criteria for the pilot study were adult patients presenting to a Level 1 trauma center 
with external force trauma to the head and clinically indicated head computed tomography 
(CT) scan within 24 h of injury. Exclusion criteria were pregnancy, comorbid life-
threatening disease, incarceration, suicidal ideation/on psychiatric hold, and non-English 
speakers due to limitations in participation with outcome assessments. For the present study, 
our goal was to study the associations between COMT Val158Met and cognition after 
isolated and uncomplicated mTBI. Therefore, our analysis was restricted to a subset of 
patients with a GCS ≥13, no skull fracture, or acute intracranial pathology—defined as the 
absence of intraparenchymal contusions or hemorrhage, intraventricular hemorrhage, 
epidural hematoma, acute subdural hematoma, or traumatic subarachnoid hemorrhage—on 
non-contrasted head CT within 24 h of injury, no polytrauma as defined by an Abbreviated 
Injury Scale (AIS) score ≥3 in any extracranial body region [34, 35], as well as no prior 
history of cerebrovascular accident or transient ischemic attack, brain tumor, schizophrenia, 
learning disability or developmental delay.
Eligible subjects were enrolled through convenience sampling at all three sites. Institutional 
review board approval was obtained at all participating sites. Informed consent was obtained 
for all subjects prior to enrollment in the study. For patients unable to provide consent due to 
their injury, consent was obtained from their legally authorized representative (LAR). 
Patients were then reconsented if cognitively able at later inpatient and/or outpatient follow-
up assessments for continued participation in the study.
Biospecimen acquisition and genotyping
Specimen acquisition was performed as previously described [29]. In brief, blood samples 
for DNA genotyping analysis were collected via peripheral venipuncture or existing 
peripheral venous indwelling catheters within 24 h of injury. Samples were collected in BD 
Vacutainer K2-EDTA vacutainer tubes, and subsequently aliquoted and frozen in cryotubes 
at −80 °C within 1 h of collection in accordance with recommendations from the NIH-CDE 
Biomarkers Working Group [Manley 2010]. DNA was extracted from isolated leukocytes 
using the Wizard® Genomic DNA Purification Kit as described by the manufacturer 
(Promega, Madison, WI) and reported in our previous work [36]. COMT Val158Met 
polymorphism (rs4680) was genotyped utilizing the TaqMan®SNP Genotyping Assay as 
described by the manufacturer (Applied Biosystems, Carlsbad, CA, Assay ID# 
C_25746809_50). For the purpose of evaluating a potential protective benefit of the Met158 
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allele, Met158/Met158 and Met158/Val158 were combined as a single group as previously 
described for COMT [37–40] and other genetic polymorphisms in TBI [41–43]. Therefore, 
for data reporting and all figures, this group is referred to as Met158.
Neuropsychiatric testing and outcome parameters
The NINDS defines measures of neuropsychological impairment as those “of 
neuropsychological functions, such as attention, memory, and executive function which are 
very sensitive to effects of TBI that affect everyday activities and social role participation 
[33].” To evaluate for neuropsychological impairment, all participants underwent outcome 
assessments at 6 months following TBI with a battery of NIH NINDS-designated “Core 
Measures”—those deemed most relevant and applicable across large TBI studies. For the 
current analysis, all three measures of the “Neuropsychological Impairment” domain of the 
outcome CDEs were included:
Wechsler Adult Intelligence Scale, fourth edition Processing Speed Index Subscale
The Wechsler Adult Intelligence Scale, fourth edition Processing Speed Index Subscale 
(WAIS-PSI) is a summary measure of nonverbal processing speed and is comprised of two 
non-verbal tasks (symbol search and coding) which require visual attention and motor speed 
[44]. In studies of TBI, it has been shown to predominately reflect impairment in perceptual 
processing speed with a small component attributable to working memory and only minimal 
contribution from motor speed [45]. The composite score is scalar, ranging from 50 to 150 to 
correspond to the 0.1st to 99.9th percentile of performance across age groups. Scores of ~90, 
100, and ~110 correspond to the 25th, 50th, and 75th percentiles, respectively [44].
Trail Making Test
The Trail Making Test (TMT) is a two-part timed test (TMT-A and TMT-B), and both scores 
are measured in number of seconds needed for the patient to complete the task. TMT-A 
assesses visual processing, and TMT-B assesses mental flexibility and processing speed 
[46]. In order to derive a purer index of executive control and mental flexibility separate 
from visual processing and motor speed, we used the difference score between the Trial B 
and Trial A (TMT B-A) as previously described [47–49]. In this test, a lower score suggests 
improved performance.
California Verbal Learning Test, second edition
The California Verbal Learning Test, second edition (CVLT-II) is a verbal learning and 
memory task in which five learning trials, an interference trial, an immediate recall trial, and 
a post-20 min recall trial are performed. The CVLT-II trials 1–5 Standard Score is a 
summative score of the first five learning trials normed for age and sex and provides a global 
index of verbal learning ability [50]. The CVLT-II was substituted for the Rey Auditory 
Verbal Learning Test (RAVLT) listed in the NIH NINDS outcome CDEs due to relevant 
revisions of the second edition and higher consistency on between-norm sets [51].
Winkler et al. Page 5
Neurogenetics. Author manuscript; available in PMC 2017 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Statistical analysis
Group differences in patient demographics and mechanism of injury across COMT Met158 
carriers versus Val158/Val158 homozygotes were assessed by Pearson’s chi-squared test (X2) 
for categorical variables and analysis of variance (ANOVA) for continuous variables. 
Fisher’s exact test was used to assess for differences in categorical variables with group 
counts ≤5. Means and standard deviations are reported for continuous descriptive variables. 
Group differences are reported between COMT genotype and each outcome measure using 
ANOVA. Multivariable linear regression was performed for each of the three outcome 
measures to adjust for age and education years as recommended [44–46, 49, 50]; the WAIS-
PSI Composite Score and CVLT-II trials 1–5 Standard Score are already age-normed and 
thus further adjusted only for education years, while the TMT B-A score was further 
adjusted for age and education years. As this is a study of mTBI, the GCS was used to adjust 
for injury severity (GCS 15 vs. less than 15). The adjusted unstandardized coefficient of 
regression (B) and associated standard error (SE) was used to quantify mean increase or 
decrease in the outcome measure associated with a per-unit increase in a continuous 
predictor or a change in the subcategory of a categorical predictor. All multivariable 
regression models conformed to tests for goodness-of-fit. To account for race stratification, 
race was entered onto the multivariable regression with three subcategories to include the 
two largest race categories (Caucasian, African-American/African) as well as a third 
category of aggregated “other races” for races with small (<5) group counts. Significance 
was assessed at α=0.05. All analyses were performed using Statistical Package for the 
Social Sciences (SPSS) v.22 (IBM Corporation, Chicago, IL). Figures were constructed with 
GraphPad Prism v.6 (GraphPad Software, La Jolla, CA).
Results
Patient demographics and mechanisms of injury
In total, the present study included 100 subjects (Table 1). Overall, subjects had a mean age 
of 40.9 years (SD 15.2) and were 66 % male. The race distribution was 70 % Caucasian, 
14 % African American/African, 5 % Asian, 1 % American Indian/Alaskan Native, 1 % 
Hawaiian/Pacific Islander, and 9 % more than one race. Subjects had a mean of 14.2 years of 
education (SD 2.9). Mechanisms of injury were 33 % fall, 26 % motor vehicle crash, 22 % 
pedestrian versus auto, 15 % assault, and 4 % struck by/against object. GCS distribution was 
3, 20, and 77 % for GCS of 13, 14, and 15, respectively. Distribution of admission GCS did 
not change with respect to genotype. For injury severity classification, GCS of 13 and 14 
were combined into a single group of “GCS less than 15″. There was also no difference in 
posttraumatic amnesia—another important predictor for posttraumatic cognitive impairment
—across genotypes [11, 52–54]. In total, 66 subjects were discharged from the emergency 
department (ED), 30 were admitted to the hospital ward, and 4 were admitted to the 
intensive care unit (ICU). No statistically significant difference in ED disposition was 
observed across genotypes (Table 1).
COMT genotype distribution was 29 % Met158/Met158 (n= 29), 47 % Met158/Val158 (n=47), 
and 24 % Val158/Val158 (n= 24). COMT allelic frequencies (A=0.53, G=0.47) were not 
found to deviate significantly from Hardy-Weinberg equilibrium (X2=0.33, p=0.566). Years 
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of education were higher for Met158 carriers than for Val158/Val158 homozygotes (p=0.016), 
and a higher prevalence of Val158/Val158 homozygotes was noted in African-American/
African subjects (p=0.042). No other significant differences were observed in the 
distribution of each demographic and clinical descriptor across COMT Met158 and 
Val158/Val158 genotypes (Table 1).
Outcome measures
We first assessed whether the COMT Val158Met polymorphism was associated with 
divergent performance on three primary cognitive measures—WAIS-PSI, TMT B-A, and 
CVLT-II—following isolated, uncomplicated mTBI. COMT Met158 carriers showed 
significantly higher nonverbal processing speed on WAIS-PSI when compared to COMT 
Val158/Val158 homozygotes (Met158 103.8±13.3; Val158/ Val158 94.1±15.7; p=0.004) (Table 
2). COMT Met158 subjects did not associate with a task requiring mental flexibility on TMT 
B-A (Met158 46.6±51.5; Val158/Val158 63.8±42.0, p=0.139) (Table 2). COMT Val158Met 
polymorphism did not associate with verbal learning and fluency as measured by the CVLT-
II Trial 1–5 Standard Score (Met158 54.5±11.1; Val158/Val158 53.7±9.4, p=0.740) (Table 2).
COMT Val158Met is associated with nonverbal processing speed after mTBI
To further assess the association between COMT Val158Met and nonverbal processing speed 
as measured by the WAIS-PSI composite score, multivariable regression was performed to 
control for education years, race, and injury severity (Table 3). COMT Met158 carriers 
demonstrated higher adjusted mean scores on WAIS-PSI (101.6±2.1) compared to their 
Val158/Val158 counterparts (93.8±3.0), which corresponds to a mean increase of 7.9 points 
(95 % CI [1.4 to 14.3], p=0.017) (Fig. 1). Consistent with prior reports [55–57], education 
years associated with WAIS-PSI (B=1.4, 95 % CI [0.4 to 2.3], p=0.005). Greater injury 
severity also associated with a decrease in nonverbal processing speed (GCS 15, 101.6±1.9; 
GCS <15, 93.8±3.0; B=−7.9, 95 % CI [−14.1 to −1.7], p= 0.013). Race did not show a 
significant association with WAIS-PSI (p=0.539) on multivariable analysis. Further, 
multivariable subgroup analysis performed in the Caucasian group—the largest group—
demonstrated a statistical trend between the COMT Val158Met polymorphism and 
performance on WAIS-PSI (B=7.5, 95 % CI [−1.1 to 16.0], p= 0.086). Future studies are 
needed to confirm this finding in a larger population.
COMT Val158Met is not associated with mental flexibility after mTBI
To further assess the association between COMT Val158Met and mental flexibility as 
measured by the TMT B-A time, multivariable regression was performed to control for 
education years, race, and injury severity. Since the TMT B-A has not been intrinsically 
adjusted for age, we further adjusted for age in the current analysis. COMT Val158Met did 
not demonstrate an association with TMT B-A after adjustment (Met158 47.7±7.1; 
Val158/Val158 58.8±10.2; B=−11.1, 95 % CI [−33.0 to 10.8], p=0.318) (Table 3). Consistent 
with prior reports [58, 59], both age years (B=1.2, 95 % CI [0.6 to 1.8], p<0.001) and 
education years (B=−5.2, 95 % CI [−8.4 to −2.0], p=0.002) associated with decreased and 
increased performance on mental flexibility, respectively. Injury severity did not show a 
significant association with TMT B-A (GCS 15 47.5±6.5; GCS <15 59.0±10.3; B=11.5, 
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95 % CI [−9.7 to 32.6], p=0.284). Race did not show a significant association with TMT B-
A (p=0.492) on multivariable analysis.
COMT Met158 is not associated with verbal learning after mTBI
To further assess the association between COMT Val158Met and verbal learning as measured 
by the CVLT-II, multivariable regression was performed to control for education years, race, 
and injury severity. COMT Val158Met did not demonstrate an association with CVLT-II after 
adjustment (Met158 50.9±1.6; Val158/Val158 51.6±2.4; B=−0.7, 95 % CI [−5.8 to 4.3], 
p=0.771) (Table 3). Consistent with prior reports [60], education years (B=0.6, 95 % CI 
[−0.1 to 1.4], p=0.098) showed a borderline association with verbal learning. Greater injury 
severity also associated with a decrease in verbal learning (GCS 15 53.7±1.5; GCS <15 
48.7±2.4; B=−5.0, 95 % CI [−9.9 to −0.1], p=0.044). Race showed a borderline significant 
association with CVLT-II (p=0.068) on multivariable analysis, driven primarily by a 
difference between the Caucasian subgroup and the heterogeneous “other races” subgroup 
(B=−5.9 [−11.5 to −0.2], p=0.042).
Discussion
In the present study, we sought to investigate whether the COMT Val158Met polymorphism 
is associated with cognitive performance at 6 months following mild closed head injury in 
an isolated, uncomplicated mTBI population. We found that subjects with the COMT Met158 
allele showed higher performance on a measure of nonverbal processing speed compared to 
Val158/Val158 homozygotes at 6 months following injury independent of injury severity and 
race. We also demonstrate that the COMT Val158Met polymorphism is not associated with a 
measure of executive control and mental flexibility or a measure of verbal learning after 
controlling for injury severity and race. We confirm that greater injury severity is associated 
with poorer nonverbal processing speed and verbal learning. Further, racial stratification was 
not found to significantly associate with nonverbal processing speed, mental flexibility, or 
verbal learning after uncomplicated mTBI in the current patient population.
In our current analysis, COMT Met158 carriers showed an adjusted mean score of 101.6 on 
the WAIS-PSI, while Val158/ Val158 homozygotes showed 93.8—these scores correspond to 
the ~55th percentile and the ~34th percentile of nonverbal processing speed performance in 
the normal population, respectively [44]. We also find that the adjusted mean scores (~50 s) 
on the CVLT-II correspond to the general mean of the normal population for both COMT 
Val158Met groups [50]. Further, the adjusted TMT B-A times for both COMT groups fall 
within the means reported in literature (~40 to ~60) for the normal/uninjured population [49, 
61, 62]. Thus, it is worth noting that a subgroup of patients with isolated uncomplicated 
mTBI demonstrates heightened risk for decreased performance on nonverbal processing, but 
not verbal learning or executive function at 6 months postinjury, and this subgroup 
associates with the common SNP COMT Val158Met.
It is generally accepted that acute physiologic recovery occurs by 6 months post-mTBI on 
imaging studies [9, 63, 64], and studies report that most cognitive symptoms resolve by 
within the first 3 months in mTBI [65, 66]. To our knowledge, this is the first study of the 
association between COMT Val158Met and cognitive performance at an extended time point 
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of recovery, such as 6 months following mTBI. Prior reports examining the potential 
influence of the COMT Val158-Met polymorphism on TBI cognitive outcomes have been 
conducted during acute and subacute recovery with a mean time of collection within 2 
months postinjury and have been predominately limited to patients with moderate and/or 
severe injuries [17, 18, 67]. For example, in a cohort of 113 TBI rehabilitation patients 
assessed at a mean of 2 months postinjury,17 Val158/Val158 homozygotes were found to score 
lower on a measure of cognitive flexibility—the ability to alter a behavioral response against 
changing contingencies [68]—and to have a greater number of perseverative errors. In 
another sample of 32 moderate-to-severe TBI patients with 40 health controls, COMT 
Met158 was found to associate with preserved strategic control of attention at 2 months 
postinjury [67]. In the largest study of COMT and moderate-to-severe TBI to date, Willmott 
et al. did not find an association between COMT and measures of cognition at roughly 1 
month postinjury [18]. However, this study evaluated cognitive performance at a time point 
that was not standardized and closer to the time of injury (mean 29 days); the authors 
suggest that cognitive assessment at 6–12 months postinjury may be more likely to detect 
subtle group differences as demonstrated in the present report.
There is physiological evidence in support of a potential modulatory role of the COMT 
Met158 allele in cognitive performance following TBI. The PFC is a key center for overall 
executive function, attention, and strategic planning [69–71], in which its rich dopaminergic 
pathways are more dependent on COMT for regulation and modulation at the synaptic cleft 
[19–21]. Prior studies have demonstrated that the COMT Val158Met polymorphism is 
associated with differences in cognitive performance in the absence of brain injury [23, 72]. 
Given the absence of measures of baseline preinjury performance in our population or 
neuropsychiatric data in appropriately uninjured age-matched controls, we cannot conclude 
whether our results reflect the maintenance of preexisting cognitive differences between 
genotypes and/or an altered trajectory of recovery or impairment following mTBI.
There are also several additional limitations to the present study. Our data was obtained for a 
relatively small sample size (n=100) in a predominately Caucasian male population and did 
not conform to known HapMap Phase III subpopulations; therefore, there is a need for 
studies of confirmation in similar populations and of validation in larger and more diverse 
study populations. We also included patients only with isolated mTBI in the absence of 
intracranial findings on CT and a limited period of diminished consciousness and/or 
posttraumatic amnesia; thus, the generalizability of our results is limited. We also include no 
neuroimaging outside of 24 h or magnetic resonance imaging. Therefore, it is possible that a 
subset of the subjects developed delayed pathology on neuroimaging and would no longer be 
classified as uncomplicated. We pursued analyses designed to investigate a hypothesized 
relationship between the COMT Val158Met polymorphism and cognitive outcome and did 
not explore the structure-function implications of COMT with specific brain pathology or 
variables important to the trajectory of recovery such as treatment and support. There is also 
a need to examine gene-gene interaction with other susceptibility loci in the context of mTBI 
to better elucidate complex interactions and mechanisms through which the COMT 
molecular pathway may influence response and recovery to TBI. Finally, all of our findings 
must be considered preliminary until they are formally replicated.
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Conclusions
The COMT Val158Met polymorphism (rs4680) is associated with nonverbal cognitive 
performance following uncomplicated mTBI without polytrauma. More specifically, the 
COMT Met158 allele is associated with increased performance in nonverbal processing 
speed, while no associations were seen on mental flexibility or verbal learning. Larger 
studies in similar populations will be of value to confirm the role of COMT Val158Met 
polymorphism in these domains and to explore its effects in other cognitive domains 
following mTBI. Whether COMT Val158/Val158 homozygotes would benefit from 
heightened clinical surveillance and/or pharmacologic and cognitive behavior therapy 
remains to be determined and may represent an important direction of future studies.
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TRACK-TBI Investigators
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Fig. 1. 
COMT Val158Met and 6-month WAIS-PSI Composite Score after mild traumatic brain 
injury. The COMT Val158Met polymorphism is associated with statistically greater 
preservation of nonverbal processing speed 6 months following mild traumatic brain injury 
after adjusting for race, years of education, and injury severity. Means and standard errors on 
the WAIS-PSI Composite Score are shown for Met158 and Val158/Val158 genotype groups. 
COMT, Catechol-O-Methyltransferase, WAIS-PSI Wechsler Adult Intelligence Scale Fourth 
Edition—Processing Speed Index. *p<0.05.
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Table 1
Demographic and clinical information of included subjects with mild traumatic brain injury
Variable COMT Met158 (N=76) COMT Val158/Val158 (N=24) Sig. (p)
Age (years)
 Mean±SD 40.5±15.7 42.2±14.1 0.643
Gender
 Male 49 (65 %) 17 (71 %) 0.566
 Female 27 (35 %) 7 (29 %)
Race
 Caucasian 57 (81 %) [a] 13 (19 %) [a] 0.042
 African-American/African 7 (50 %) [a] 7 (50 %) [b]
 Other races 12 (75 %) [a] 4 (25 %) [a]
Education (years)
 Mean±SD 14.6±2.7 13.0±3.1 0.015
Mechanism of injury
 Motor vehicle crash 24 (32 %) 2 (8 %) 0.110
 Pedestrian versus auto 17 (22 %) 5 (21 %)
 Fall 23 (30 %) 10 (42 %)
 Assault 9 (12 %) 6 (25 %)
 Struck by/against object 3 (4 %) 1 (4 %)
Posttraumatic amnesia
 No 30 (40 %) 11 (46 %)
 Yes 42 (55 %) 10 (42 %) 0.310
 Unknown 4 (5 %) 3 12 %)
GCS—fielda
 <15 21 (36 %) 6 (35 %) 0.982
 =15 38 (64 %) 11 (65 %)
GCS—ED arrival
 <15 19 (25 %) 4 (17 %) 0.579
 =15 57 (75 %) 20 (83 %)
ED disposition
 ED discharge 53 (70 %) 13 (54 %) 0.284
 Hospital ward admission 20 (26 %) 10 (42 %)
 ICU admission 3 (4 %) 1 (4 %)
Race distributions are reported as row percentages. All other distributions reported as column percentages. The race subgroup “other races” was 
combined due to individual small sample sizes of Asian (N=5; Met158 =4, Val158 /Val158 =1), American Indian/Alaskan Native (N=1; Met158 
=1), Hawaiian/Pacific Islander (N=1; Met158 =1), and more than one race (N=9; Met158 =6, Val158 /Val158 =3)
COMT catechol-O-methyltransferase, ED emergency department, GCS Glasgow Coma Scale, ICU intensive care unit, SD standard deviation
a
Data for GCS—Field was only available for 76 patients
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Table 2
Distribution of performance on 6-month cognitive outcome measures following mild traumatic brain injury by 
COMT genotype
Outcome Measure Met158 (N=76) Val158/Val158 (N=24) Sig. (p)
WAIS-PSI Composite Scorea 103.8±13.3 94.1±15.7 0.004
TMT Trail B minus A Timeb 46.6±51.5 63.8±42.0 0.139
CVLT-II Trial 1–5 Standard Scorea 54.5±11.1 53.7±9.4 0.740
Distributions are reported as mean±standard deviation
COMT catechol-O-methyltransferase, CVLT-II California Verbal Learning Test, second edition, TMT Trail Making Test, WAIS-PSI Wechsler 
Adult Intelligence Scale, fourth edition, Processing Speed Index
a
Higher scores suggest improved performance
b
Lower scores suggest improved performance
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Table 3
Multivariable analysis of the COMT Val158Met polymorphism and 6-month cognitive outcome following mild 
traumatic brain injury
WAIS-PSI Composite Scorea Mean±SE B [95 % CI] Sig. (p)
COMT Val158Met 0.017
 Val158/Val158 93.8±3.0 Reference –
 Met158 101.6±2.1 7.9 [1.4, 14.3]
GCS 0.013
 GCS=15 101.6±1.9 Reference –
 GCS <15 93.8±3.0 −7.9 [−14.1, −1.7]
Race 0.539
 Caucasian 96.8±2.1 Reference –
 African-American/African 95.8±3.6 −1.1 [−9.0, 6.9] 0.790
 Other 100.5±3.5 3.7 [−3.5, 10.9] 0.312
Education (years) – 1.4 [0.4, 2.3] 0.005
TMT Trail B minus A Timeb Mean±SE B [95 % CI] Sig. (p)
COMT Val158Met 0.318
 Val158/Val158 58.8±10.2 Reference –
 Met158 47.7±7.1 −11.1 [−33.0, 10.8]
GCS 0.284
 GCS=15 47.5±6.5 Reference –
 GCS <15 59.0±10.3 11.5 [−9.7, 32.6]
Race 0.492
 Caucasian 59.2±7.1 Reference –
 African-American/African 43.0±12.3 −16.2 [−43.1, 10.7] 0.235
 Other 57.4±12.2 −1.8 [−27.0, 23.4] 0.888
Education (years) – −5.2 [−8.4, −2.0] 0.002
Age (years) – 1.2 [0.6, 1.8] <0.001
CVLT-II Trial 1–5 Standard Scorea Mean±SE B [95 % CI] Sig. (p)
COMT Val158Met 0.771
 Val158/Val158 51.6±2.4 Reference –
 Met158 50.9±1.6 −0.7 [−5.8, 4.3]
GCS 0.044
 GCS =15 53.7±1.5 Reference –
 GCS <15 48.7±2.4 −5.0 [−9.9, −0.1]
Race 0.068
 Caucasian 54.7±1.6 Reference –
 African-American 50.1±2.8 −4.7 [−10.9, 1.5] 0.139
 Other 48.9±2.8 −5.9 [−11.5, −0.2] 0.042
Education (years) – 0.6 [−0.1, 1.4] 0.098
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The WAIS Processing Speed Index (WAIS-PSI) Composite Score and the CVLT-II Trial 1–5 Standard Score are adjusted for education years, race 
(Caucasian, African-American/African, other races), and GCS (15 vs. less than 15). The TMT Trail B minus ATime is adjusted for age, education 
years, race, and GCS. Distributions are reported as adjusted mean±standard error. The mean difference (B) between COMT Met158 and COMT 
Val158 /Val158 and associated 95 % CI is reported for each outcome measure CVLT-II, California Verbal Learning Test, Second Edition; TMT, 
Trail Making Test; WAIS, Wechsler Adult Intelligence Scale, Fourth Edition.
CI confidence interval, COMT catechol-O-methyltransferase, CVLT-II California Verbal Learning Test, second edition, GCS Glasgow Coma Scale, 
TMT Trail Making Test, WAIS Wechsler Adult Intelligence Test
a
Higher scores suggest improved performance
b
Lower scores suggest improved performance
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